All posts by: Michael Zand

About Michael Zand

Check Out The Agenda for What’s Hot in Cancer Immunotherapy 2017 – Xconomy

Continue reading

2017-05-18 NEWS

Xconomy

Check Out The Agenda for What’s Hot in Cancer Immunotherapy 2017
Xconomy
We have posted the agenda for What’s Hot in Cancer Immunotherapy 2017, which is taking place on June 14 at the Fred Hutchinson Cancer Research Center in Seattle. Xconomy is gathering some of the field’s experts to assess the past and future …

Continue reading

2017-05-18 NEWS

Xconomy

Check Out The Agenda for What’s Hot in Cancer Immunotherapy 2017
Xconomy
We have posted the agenda for What’s Hot in Cancer Immunotherapy 2017, which is taking place on June 14 at the Fred Hutchinson Cancer Research Center in Seattle. Xconomy is gathering some of the field’s experts to assess the past and future …

Continue reading

2017-05-18 NEWS

Medical Xpress

Cancer immunotherapy may work in unexpected way
Medical Xpress
“Using antibodies to PD-1 or PD-L1 is one of the major advances in cancer immunotherapy,” said Weissman, who is also the Virginia and D.K. Ludwig Professor for Clinical Investigation in Cancer Research, director of the Stanford Institute for Stem Cell …
NantKwest Appoints Dr. John Lee as Senior Vice President of Adult Medical AffairsBusiness Wire (press release)
Cancer patients given hope by new trialsDaily Echo

all 2 news articles »

Continue reading

2017-05-18 NEWS

Beyond just promise, CRISPR is delivering in the lab today
Bloomington Pantagraph
CRISPR was Science magazine’s 2015 Breakthrough of the Year; it’s been featured prominently in the New Yorker morethanonce; and The Hollywood Reporter revealed that Jennifer Lopez will be the executive producer on an upcoming CRISPR-themed …

Continue reading

2017-05-18 NEWS

The Conversation US

Beyond just promise, CRISPR is delivering in the lab today
The Conversation US
Researchers are starting to harness the potential of this much-hyped gene editing technique – with coming applications in medicine, biology and agriculture.

and more »